Limited Time Offer
Get $1000 towards your
first investment
Start investing in private markets with Linqto – your access to disruptive startups and pre-IPO companies.
*Terms and conditions apply. See details
Pear Therapeutics, founded in 2013 and headquartered in Boston, Massachusetts, is a pioneering company in the field of prescription digital therapeutics (PDTs). We specialize in developing and commercializing software-based medicines designed to improve patient outcomes, enhance clinician engagement, and provide cost-effective solutions for payers. The company's focus areas include substance use disorder, opioid use disorder, and chronic insomnia.
Since its inception, Pear Therapeutics has made significant strides in the healthcare technology sector, raising a total of $334.94 million in funding. This substantial investment underscores the potential of their innovative approach to digital health solutions. The company's unique position in the market has garnered attention from both the healthcare and investment communities.
However, it's important to note that in April 2023, Pear Therapeutics filed for bankruptcy. This development significantly impacts any potential plans for an initial public offering (IPO). Given the current circumstances, we cannot provide any information or speculation about the company's IPO prospects.
The bankruptcy filing represents a major shift in the company's trajectory and will likely have far-reaching implications for its future operations and potential investment opportunities. As the situation continues to evolve, interested parties should closely monitor official announcements and financial reports for the most up-to-date and accurate information regarding Pear Therapeutics' status and any potential future plans.
Get $1000 towards your
first investment
*Terms and conditions apply. See details
While Pear Therapeutics' IPO prospects remain uncertain, investors eager to explore opportunities in the digital therapeutics space don't have to wait. At Linqto, we offer members access to interests in promising private companies before they go public. Our platform provides the opportunity to invest in potential leaders in the healthcare technology sector, including companies like Pear Therapeutics, with lower minimum investments than traditional private equity opportunities. This allows you to potentially benefit from their growth and innovation before they hit the public markets.
*These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO. The information provided above is based on current online discussions and is not intended as investment advice. Linqto does not endorse or guarantee the accuracy of this information, and we strongly recommend conducting your own research or consulting with a professional advisor before making any investment decisions. Linqto cannot be held liable for any investment outcomes resulting from the use of this information.
